Biomarkers /
PPFIBP2
Overview
PPFIBP2 is altered in 0.21% of all cancers with lung adenocarcinoma, thyroid gland papillary carcinoma, breast invasive ductal carcinoma, low-grade glioma, NOS, and pancreatic adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in PPFIBP2 are PPFIBP2-BRAF Fusion (0.14%), PPFIBP2-RET Fusion (0.10%), and PPFIBP2-CIITA Fusion (0.04%) [3].
Clinical Trials
Significance of PPFIBP2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.